Effect of tezepelumab on symptoms and peak expiratory flow before, during and after exacerbations in NAVIGATOR
M. Castro (Kansas City, KS, United States), N. Martin (Leicester, United Kingdom), C. Ambrose (Gaithersburg, MD, United States), S. Ponnarambil (Cambridge, United States), A. Kotalik (Gaithersburg, MD, United States), J. Llanos-Ackert (Thousand Oaks, CA, United States), S. Korn (Heidelberg, Germany)
Source: International Congress 2022 – Translational studies of asthma and COPD
Session: Translational studies of asthma and COPD
Session type: Thematic Poster
Number: 4312
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Castro (Kansas City, KS, United States), N. Martin (Leicester, United Kingdom), C. Ambrose (Gaithersburg, MD, United States), S. Ponnarambil (Cambridge, United States), A. Kotalik (Gaithersburg, MD, United States), J. Llanos-Ackert (Thousand Oaks, CA, United States), S. Korn (Heidelberg, Germany). Effect of tezepelumab on symptoms and peak expiratory flow before, during and after exacerbations in NAVIGATOR. 4312
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|